[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2016130611A3 - - Google Patents

Download PDF

Info

Publication number
RU2016130611A3
RU2016130611A3 RU2016130611A RU2016130611A RU2016130611A3 RU 2016130611 A3 RU2016130611 A3 RU 2016130611A3 RU 2016130611 A RU2016130611 A RU 2016130611A RU 2016130611 A RU2016130611 A RU 2016130611A RU 2016130611 A3 RU2016130611 A3 RU 2016130611A3
Authority
RU
Russia
Application number
RU2016130611A
Other languages
Russian (ru)
Other versions
RU2016130611A (en
RU2697094C2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016130611A publication Critical patent/RU2016130611A/en
Publication of RU2016130611A3 publication Critical patent/RU2016130611A3/ru
Application granted granted Critical
Publication of RU2697094C2 publication Critical patent/RU2697094C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2016130611A 2013-12-27 2014-12-27 ARTIFICIAL miRNA WITH CONFORMITY FOR GENE EXPRESSION CONTROL AND USE THEREFOR RU2697094C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-273033 2013-12-27
JP2013273033 2013-12-27
PCT/JP2014/084724 WO2015099187A1 (en) 2013-12-27 2014-12-27 Artificial match-type mirna for controlling gene expression and use therefor

Publications (3)

Publication Number Publication Date
RU2016130611A RU2016130611A (en) 2018-01-31
RU2016130611A3 true RU2016130611A3 (en) 2018-08-27
RU2697094C2 RU2697094C2 (en) 2019-08-12

Family

ID=53479025

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016130611A RU2697094C2 (en) 2013-12-27 2014-12-27 ARTIFICIAL miRNA WITH CONFORMITY FOR GENE EXPRESSION CONTROL AND USE THEREFOR

Country Status (13)

Country Link
US (1) US10934542B2 (en)
EP (1) EP3088525A4 (en)
JP (2) JP6425142B2 (en)
KR (1) KR102357337B1 (en)
CN (2) CN112646812A (en)
AU (1) AU2014370829B2 (en)
BR (1) BR112016014986A2 (en)
CA (1) CA2935022A1 (en)
IL (2) IL246395B (en)
MX (1) MX2016008518A (en)
RU (1) RU2697094C2 (en)
SG (3) SG10201805087VA (en)
WO (1) WO2015099187A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013180038A1 (en) 2012-05-26 2013-12-05 株式会社ボナック Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
CN105899663B (en) 2013-12-26 2019-07-26 学校法人东京医科大学 Manual simulation miRNA and application thereof for gene expression control
US10934542B2 (en) 2013-12-27 2021-03-02 Bonac Corporation Artificial match-type miRNA for controlling gene expression and use therefor
RU2740032C2 (en) * 2014-12-27 2020-12-30 Бонак Корпорейшн Naturally occurring in nature sirna to control gene expression and use thereof
ES2926369T3 (en) 2015-03-27 2022-10-25 Bonac Corp Single-stranded nucleic acid molecule that has a delivery function and ability to control gene expression
WO2016167366A1 (en) * 2015-04-17 2016-10-20 国立大学法人 東京大学 Therapeutic agent for eye disease
WO2017073767A1 (en) * 2015-10-30 2017-05-04 株式会社ボナック COMPOSITION STABLY CONTAINING SINGLE-STRANDED NUCLEIC ACID MOLECULE THAT SUPPRESSES EXPRESSION OF TGF-β1 GENE
TW202334427A (en) 2016-01-26 2023-09-01 日商日產化學工業股份有限公司 Single-stranded oligonucleotide
CA3013179A1 (en) * 2016-01-30 2017-08-03 Bonac Corporation Artificial single guide rna and use thereof
EP3584319A4 (en) * 2017-02-06 2021-04-14 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2018155487A1 (en) * 2017-02-21 2018-08-30 株式会社ボナック Nucleic acid-containing powdery preparation for dpi, and use thereof
TWI830718B (en) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 Method of producing nucleic acid molecule
WO2019182037A1 (en) 2018-03-20 2019-09-26 国立大学法人東京工業大学 Antisense oligonucleotide having reduced toxicity

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE873543C (en) 1942-10-28 1953-04-16 Basf Ag Process for the production of dicarbamic acid esters containing hydroxyl or sulfhydryl groups
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4550163A (en) 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US20030232355A1 (en) 1992-05-22 2003-12-18 Isis Pharmaceuticals, Inc. Double-stranded peptide nucleic acids
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
GB9621367D0 (en) 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6197557B1 (en) 1997-03-05 2001-03-06 The Regents Of The University Of Michigan Compositions and methods for analysis of nucleic acids
EP1013770A1 (en) 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
FR2790757B1 (en) 1999-03-09 2003-08-01 Bioalliance Pharma OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
EP1748078B1 (en) 2001-03-09 2011-01-19 Boston Probes, Inc. Methods, kits and compositions of combination oligomers
EP1627061B1 (en) 2001-05-18 2009-08-12 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20050233455A1 (en) 2001-10-29 2005-10-20 Damha Masad J Acyclic linker-containing oligonucleotides and uses thereof
AU2003219900A1 (en) 2002-02-22 2003-09-09 James R. Eshleman Antigene locks and therapeutic uses thereof
EP1495141A4 (en) 2002-03-20 2006-03-22 Massachusetts Inst Technology Hiv therapeutic
BRPI0313202A8 (en) 2002-08-05 2016-08-16 Atugen Ag ADDITIONAL WAYS TO INTERFERE WITH RNA MOLECULES
AU2003256857A1 (en) * 2002-08-08 2004-02-25 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
JP2006522158A (en) 2003-04-03 2006-09-28 アルナイラム ファーマシューティカルズ インコーポレイテッド iRNA complex
EP1641942A2 (en) 2003-06-12 2006-04-05 Applera Corporation Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same
WO2005047505A2 (en) 2003-08-07 2005-05-26 Whitehead Institute For Biomedical Research Methods and products for expression of micro rnas
US7595301B2 (en) 2003-09-30 2009-09-29 Anges Mg, Inc. Staple type oligonucleotide and drug comprising the same
WO2005035550A2 (en) 2003-10-14 2005-04-21 Kernel Biopharma Inc. Dual phase-pna conjugates for the delivery of pna through the blood brain barrier
US20050209141A1 (en) 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
AU2005327517B2 (en) 2004-06-30 2011-05-26 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
CA2578064C (en) 2004-08-23 2015-10-13 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
EP1783137A4 (en) 2004-08-26 2014-10-22 Nippon Shinyaku Co Ltd Galactose derivative, drug carrier and medicinal composition
EP2287301A3 (en) 2004-08-31 2011-11-02 Sylentis S.A.U. Methods and compositions to inhibit P2X7 receptor expression
CN101076592B (en) 2004-10-12 2013-08-21 洛克菲勒大学 Micro rna
ES2507544T3 (en) 2004-11-12 2014-10-15 Asuragen, Inc. Procedures and compositions involving miRNA and miRNA inhibitor molecules
BRPI0519690A2 (en) 2004-12-30 2009-03-03 Todd M Hauser compositions and methods for modulating gene expression using self-protected oligonucleotides
ATE455784T1 (en) 2006-03-01 2010-02-15 Nippon Shinyaku Co Ltd GALACTOSE DERIVATIVE, DRUG CARRIER AND MEDICAL COMPOSITION
US9045754B2 (en) 2006-05-05 2015-06-02 Isis Pharmaceuticals, Inc. Short antisense compounds with gapmer configuration
EP2194128B1 (en) * 2006-05-11 2012-08-01 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
EP1890152A1 (en) 2006-08-14 2008-02-20 Charite Universitätsmedizin-Berlin Determination of renin/prorenin receptor activity
JP2008220366A (en) 2007-02-16 2008-09-25 National Institute Of Advanced Industrial & Technology Modification type pna/rna complex
JP5145557B2 (en) 2007-03-01 2013-02-20 財団法人ヒューマンサイエンス振興財団 Tumor growth inhibitor containing microRNA as active ingredient, and pharmaceutical composition for cancer treatment
EP2129680B1 (en) 2007-03-21 2015-05-06 Brookhaven Science Associates, LLC Combined hairpin-antisense compositions and methods for modulating expression
CN101121934B (en) 2007-04-11 2011-12-07 哈尔滨医科大学 Multiple target points miRNA antisense nucleic acid technique
US8258286B2 (en) 2007-04-26 2012-09-04 University Of Iowa Research Foundation Reduction of off-target RNA interference toxicity
EP2152722B1 (en) * 2007-05-03 2016-04-27 Merck Sharp & Dohme Corp. Compositions comprising mir34 therapeutic agents for treating cancer
JP5296328B2 (en) 2007-05-09 2013-09-25 独立行政法人理化学研究所 Single-stranded circular RNA and method for producing the same
US20090123501A1 (en) 2007-05-17 2009-05-14 Baylor College Of Medicine Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
US8841267B2 (en) 2007-05-23 2014-09-23 Ge Healthcare Dharmacon, Inc. Micro-RNA scaffolds, non-naturally occurring micro-RNAs, and methods for optimizing non-naturally occurring micro-RNAs
EP2171089B1 (en) 2007-06-25 2014-01-22 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
WO2009029690A1 (en) * 2007-08-27 2009-03-05 Boston Biomedical, Inc. Composition of asymmetric rna duplex as microrna mimetic or inhibitor
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
AU2008309520A1 (en) 2007-10-12 2009-04-16 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Method for opening tight junctions
TW200927177A (en) 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect
AR069328A1 (en) 2007-11-15 2010-01-13 Alcon Mfg Ltd RELEASE OF SHORT OR SIRNA INTERFERENT RNA, INTERMEDIATED BY LOW DENSITY LIPOPROTEIN RECEPTOR
WO2009074076A1 (en) 2007-11-29 2009-06-18 Suzhou Ribo Life Science Co., Ltd A complex molecule interfering the expression of target genes and its preparing methods
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20110159586A1 (en) 2007-12-07 2011-06-30 Halo-Bio Rnai Therapeutics, Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
EP2256191A4 (en) 2008-02-15 2011-07-06 Riken Cyclic single-stranded nucleic acid complex and method for producing the same
CA2719963A1 (en) 2008-03-31 2009-10-08 National Institute Of Advanced Industrial Science And Technology Double-stranded lipid-modified rna having high rna interference effect
US20110172295A1 (en) 2008-04-11 2011-07-14 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING
WO2009143619A1 (en) 2008-05-27 2009-12-03 Chum Methods of treating or preventing obesity and obesity-related hypertension
WO2010056737A2 (en) 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
JP5794559B2 (en) 2008-11-19 2015-10-14 国立大学法人岐阜大学 Drugs for regulating differentiation of mesenchymal cells and use thereof
US8426581B2 (en) 2009-03-27 2013-04-23 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of the FCεR1α gene
ES2804764T3 (en) 2009-06-01 2021-02-09 Halo Bio Rnai Therapeutics Inc Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
US8871730B2 (en) * 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
JP2012533587A (en) 2009-07-22 2012-12-27 セニックス バイオサイエンス ゲーエムベーハー Delivery systems and conjugates for delivering compounds via naturally occurring intracellular transport pathways
WO2011028550A1 (en) 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Segmented micro rna mimetics
US20110052666A1 (en) 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
JP2012503494A (en) 2009-11-06 2012-02-09 チュン−アン ユニバーシティ インダストリー−アカデミー コーオペレイション ファンデイション Gene carriers containing nanoparticles
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
US8933046B2 (en) 2009-12-23 2015-01-13 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Influenza targets
US20110200582A1 (en) 2009-12-23 2011-08-18 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011119887A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
CN101845071B (en) 2010-03-25 2012-02-01 北京欧凯纳斯科技有限公司 Nucleoside derivative of 2' or 3' coupling amino acid, preparation method and application thereof
JP5555940B2 (en) 2010-04-14 2014-07-23 国立大学法人佐賀大学 Method for detecting proliferative diabetic retinopathy and screening method for prophylactic / therapeutic agent
JP5892608B2 (en) 2010-04-19 2016-03-23 国立研究開発法人理化学研究所 Stabilization of functional nucleic acids
EP3502254B1 (en) 2010-04-23 2024-11-06 Cold Spring Harbor Laboratory Novel structurally designed shrnas
SG196779A1 (en) 2010-07-08 2014-02-13 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
US8618073B2 (en) * 2010-07-22 2013-12-31 The University Of North Carolina At Chapel Hill Use of miR-29 for cell protection
US8691782B2 (en) * 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
CN103052711B (en) * 2010-08-03 2016-08-03 株式会社博纳克 Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
US20130253168A1 (en) 2010-08-31 2013-09-26 Steven L. Colletti Novel single chemical entities and methods for delivery of oligonucleotides
CA2819944A1 (en) * 2010-12-02 2012-06-07 Daiichi Sankyo Company, Limited Modified single-stranded polynucleotide
CN102559666B (en) 2010-12-18 2013-12-25 中国科学院上海生命科学研究院 Plant virus inhibitory artificial miRNA (microRNA) and construction and application thereof
RU2615117C2 (en) 2011-02-03 2017-04-04 Мирна Терапетикс, Инк. Double-stranded rna molecule for mir-34a activity in cell
CN102784398B (en) 2011-05-16 2014-06-18 南京大学 Composition comprising endostatin adopted as delivery system and chemically-synthesized RNA interference molecule, and application thereof
JP6011945B2 (en) 2011-05-20 2016-10-25 公一 中城 Composition comprising microRNA or expression system thereof
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
JP2013055913A (en) 2011-09-09 2013-03-28 Bonac Corp Single-stranded rna molecule for gene expression control
WO2013077446A1 (en) 2011-11-26 2013-05-30 株式会社ボナック Single-stranded nucleic acid molecule for regulating expression of gene
US9528111B2 (en) 2012-01-07 2016-12-27 Bonac Corporation Single-stranded nucleic acid molecule having amino acid backbone
JP2013153736A (en) * 2012-01-07 2013-08-15 Bonac Corp Single strand nucleic acid molecule having peptide skeleton
ES2765819T3 (en) 2012-03-04 2020-06-11 Bonac Corp Micro-RNA inhibitor
AR090905A1 (en) 2012-05-02 2014-12-17 Merck Sharp & Dohme CONJUGATES CONTAINING TETRAGALNAC AND PEPTIDES AND PROCEDURES FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES, PHARMACEUTICAL COMPOSITION
WO2013180038A1 (en) 2012-05-26 2013-12-05 株式会社ボナック Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
JP6510485B2 (en) 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション PRMT5 inhibitors and methods of their use
SG11201510565TA (en) 2013-05-22 2016-01-28 Alnylam Pharmaceuticals Inc Tmprss6 irna compositions and methods of use thereof
WO2015093495A1 (en) 2013-12-16 2015-06-25 株式会社ボナック Single-stranded nucleic acid molecule for controlling expression of tgf-β1 gene
CN105899663B (en) 2013-12-26 2019-07-26 学校法人东京医科大学 Manual simulation miRNA and application thereof for gene expression control
JP6492014B2 (en) 2013-12-27 2019-03-27 株式会社ボナック Artificial match-type miRNA for gene expression control and use thereof
US10934542B2 (en) 2013-12-27 2021-03-02 Bonac Corporation Artificial match-type miRNA for controlling gene expression and use therefor
US10119140B2 (en) 2014-04-18 2018-11-06 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods for enhancing or decreasing the levels of MIR124 and MIR29 in subjects with muscular dystrophy
RU2740032C2 (en) 2014-12-27 2020-12-30 Бонак Корпорейшн Naturally occurring in nature sirna to control gene expression and use thereof
ES2926369T3 (en) 2015-03-27 2022-10-25 Bonac Corp Single-stranded nucleic acid molecule that has a delivery function and ability to control gene expression
CA3009769C (en) 2015-12-29 2021-01-12 National University Corporation Hokkaido University Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof

Also Published As

Publication number Publication date
JP6425142B2 (en) 2018-11-21
IL246395A0 (en) 2016-08-31
JPWO2015099187A1 (en) 2017-03-23
IL246395B (en) 2020-01-30
AU2014370829A1 (en) 2016-08-11
KR102357337B1 (en) 2022-01-28
JP6653889B2 (en) 2020-02-26
EP3088525A4 (en) 2017-08-09
SG10201805087VA (en) 2018-07-30
SG10201913570XA (en) 2020-03-30
CN112646812A (en) 2021-04-13
MX2016008518A (en) 2017-01-26
JP2018145199A (en) 2018-09-20
WO2015099187A1 (en) 2015-07-02
SG11201605247XA (en) 2016-08-30
CA2935022A1 (en) 2015-07-02
KR20160121510A (en) 2016-10-19
CN106068324A (en) 2016-11-02
EP3088525A1 (en) 2016-11-02
RU2016130611A (en) 2018-01-31
IL271715B (en) 2022-03-01
US20160319282A1 (en) 2016-11-03
RU2697094C2 (en) 2019-08-12
BR112016014986A2 (en) 2018-01-23
IL271715A (en) 2020-02-27
CN106068324B (en) 2020-12-29
US10934542B2 (en) 2021-03-02
AU2014370829B2 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
BR112015007533A2 (en)
BR102016010778A2 (en)
BR112014017733A2 (en)
BR112014017739A2 (en)
BR112014018502A2 (en)
BR112014019326A2 (en)
BR112014018516A2 (en)
BR112014020341A2 (en)
BR112014018480A2 (en)
BR112014017855A2 (en)
BR112014017765A2 (en)
BR112014017669A2 (en)
BR112014021878A2 (en)
BR112014018468A2 (en)
BR112014017901A2 (en)
BR112014018207A2 (en)
BR112014019204A2 (en)
RU2016130611A3 (en)
BR112014017722A2 (en)
BR112015015948A2 (en)
BR112016009539A2 (en)
BR112014018578A2 (en)
BR112014018483A2 (en)
BR112014017794A2 (en)
BR112014017653A2 (en)